Physician profile
Jill M Powers
NPI 1912010471
$664.83
in general payments reported to CMS, 2019-2025
17 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.89 · 2020: $16.88 · 2021: $40.96 · 2022: $98.99 · 2023: $18.90 · 2024: $277 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $139.86 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.99 | 2022 | |
| Abbvie INC. | $52.47 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $45.00 | 2024 | Breztri |
| Janssen Pharmaceuticals, INC | $42.22 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $38.36 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Nevro Corp. | $33.36 | 2024 | Senza |
| Lilly USA, LLC | $32.93 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $28.65 | 2024-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $25.40 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $24.41 | 2021 | |
| Astellas Pharma US INC | $23.35 | 2024 | Veozah |
| Stryker Corporation | $17.45 | 2024 | Omnicurve |
| Allergan, INC. | $16.88 | 2020 | |
| Abbott Laboratories | $16.48 | 2024 | Freestyle Libre 3 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.67 | 2025 | Shingrix |
| Xeris Pharmaceuticals, INC. | $14.35 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.